

**PETER H. RHEINSTEIN, M.D., J.D., M.S.**  
**621 Holly Ridge Road**  
**Severna Park, Maryland 21146-3520**

Telephone: 410 647-9500  
 (from DC): 301 261-1300  
 Facsimile: 410 647-6135

Mobile: 301-792-2800  
 E-Mail: [phr@jhu.edu](mailto:phr@jhu.edu)

### **SUMMARY OF EXPERIENCE**

Current: Consultant to industry, investors and law firms. Leader in professional organizations. ([http://en.wikipedia.org/wiki/Peter\\_Rheinstein](http://en.wikipedia.org/wiki/Peter_Rheinstein)) Publisher of *Discovery Medicine*.

Previous: Senior Vice President for Medical and Clinical Affairs at biotechnology company. Twenty five years senior level experience at Food and Drug Administration with emphasis on health policy, technology transfer, medico-legal and health economics issues. Managed multiple drug regulatory activities and large staffs. Extensive experience in outreach to government agencies and organized medicine. Private practice of family medicine and geriatrics. Corporate medical director. Organized company to provide hospital emergency department coverage.

### **CURRENT POSITIONS**

President, Severn Health Solutions 10/99-present

Consultant to industry, medical publishers, investors and law firms on issues related to development and marketing of pharmaceuticals, generic drug eligibility and approval, Rx/OTC Switch and patent term restoration, reimbursement, HIPAA, Healthy People 2020, GCPs, clinical trials, medical ethics

Publisher, *Discovery Medicine* Books and Research Summaries 01/23-

Details at <https://www.discoverymedicine.com/about/scientific-editorial-advisory-board-of-discovery-medicine>

Chairman, United States Adopted Names (USAN) Council 01/12-present

USAN Council establishes the generic names for all pharmaceutical products marketed in the US. Most USAN Council names are adopted by WHO as International Nonproprietary Names (INN) (<http://www.unitedstatesadoptednames.com> and [http://en.wikipedia.org/wiki/United\\_States\\_Adopted\\_Name](http://en.wikipedia.org/wiki/United_States_Adopted_Name)).  
 USAN Council Member, 2006- ; USAN Review Board Member, 2004-05

### **RECENT PAST POSITIONS**

Publisher, *Discovery Medicine* Journal 11/01-04/23

With colleagues from Johns Hopkins Medical Institutions, started publication of a journal summarizing major advances in cutting edge research. Assembled a distinguished board of senior editors. *Discovery Medicine* is indexed at [www.pubmed.gov](http://www.pubmed.gov) as Discov Med

Clinical Research Consultant, Marnac, Inc.

07/01-06/09

Consult on design and regulatory issues for Phase II clinical trials of pirfenidone in pulmonary fibrosis and multiple sclerosis. Edit Clinical Investigator's Brochures. Elected to company's Board of Directors 08/03. Helped license pirfenidone to Shionogi (approved in Japan 02/09) and InterMune (approved in US 10/14) and wind up affairs of company.

Senior Vice President for Medical and Clinical Affairs, Cell Works Inc.

10/99-06/04

Chief Medical Officer at startup biotechnology company specializing in cancer diagnostics and therapeutics. Awarded SBIR grant as principal investigator by National Cancer Institute and Orphan Drug Designation by Food and Drug Administration both for ligand directed treatment of hepatocellular carcinoma. Organized Scientific Advisory Board. Planned strategy for development of circulating cancer cell tests to detect disease recurrence and help guide therapy. Supervised clinical trials and work of contract research organizations. Prepared and reviewed legal documents. Represented company at medical society (ASCO, Prostate Cancer Foundation, MD Anderson Tumor Markers Conference, BIO) and investor meetings.

**EXPERIENCE AT FDA, ROCKVILLE, MD**Director: Medicine Staff, Office of Health Affairs, Senior Executive Service (SES, Level IV) 1990-09/99

A principal medical spokesperson for FDA. Accountable for FDA interface with health professionals and their organizations and with other government health agencies.

- Incorporated FDA objectives into Healthy People 2000 and 2010 (US National Health Goals)
- Chair of FDA's Internal Institutional Review Board, Dramatically cut review times
- Chief hearing officer for clinical investigator disqualification hearings
- Advisor to HCFA (now CMS) on Medicare Coverage issues
- FDA representative to AHCPR (now AHRQ) National Advisory Council
- FDA representative on numerous advisory panels, both federal and non-governmental
- Responsible for The FDA Medical Bulletin (circulation 700,000) and "From the FDA" columns in journals for physicians, pharmacists and nurses
- Developed original materials and partners for MedWatch, FDA's Medical Product Reporting Program, increased number and quality of practitioner reports.
- Focal point liaison for FDA Alternative and Complementary Medicine initiatives including strategies for evaluating botanical and homeopathic compounds

Director: Office of Drug Standards, Center for Drug Evaluation and Research (SES, Level IV) 1983-1990

Managed Divisions of Drug Advertising and Labeling (now OPDP); Generic Drugs (now Office of Generic Drugs), Bioequivalence, Biopharmaceutics and OTC Drug Products

- Implemented Drug Price Competition and Patent Term Restoration Act of 1984
- Established precedents for determining patent rights and marketing exclusivity
- Responsible for review of all abbreviated new drug applications speeding review through computerization and streamlining of work flow
- Chaired meetings between FDA and Manufacturers on alleged violations of FDA regulations governing prescription drug promotion
- FDA delegate to U.S. Pharmacopeial Convention
- FDA representative to Bilateral Meetings with Japanese Drug Regulatory Authority
- Consultant to National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China, 1981-1989

Acting Director: Office of Drugs, National Center for Drugs and Biologics 12/82-10/83  
Acting Deputy Director: Office of Drugs, National Center for Drugs and Biologics 04/82-12/82

Managed 500 employees in compliance, drug research and testing, epidemiology, biostatistics, information systems, generic drugs, over-the-counter drugs, promotion and biopharmaceutics

Director: Division of Drug Advertising and Labeling, Bureau of Drugs (GM-15) 1974-1982  
 (Now Office of Prescription Drug Promotion)

Responsible for regulation of all prescription drug promotion within the US

- Finalized (still current) regulations for Rx Drug Advertising and Labeling
- Developed precedents that have remained in effect until the present day
- Initiated FDA's first patient medication information program
- Responsible for review of research studies supporting advertising claims
- For six years, chair of Bureau-wide Committee on Advanced Scientific Education winning and maintaining ACCME and ACPE accreditation

### EDUCATION

M.D.: Johns Hopkins University, Baltimore, MD, 1967  
 Teaching Asst., Dept. of Biomathematics; Research Asst., DCRT/NIH  
 Epidemiology Training Program, California Dept. of Public Health

J.D.: University of Maryland, Baltimore, MD, 1973  
 Senior Class President; Vice-President, Student Bar Association  
 Dean, Taney Senate, Delta Theta Phi Law Fraternity  
 Judge, Annual Health Law Regulatory & Compliance Competition, 2015-present  
 U of MD Francis King Carey School of Law Alumni Board, 2020-present  
[\(https://www.law.umaryland.edu/alumni--friends/get-involved/alumni-board/\)](https://www.law.umaryland.edu/alumni--friends/get-involved/alumni-board/)

M.S.: Michigan State University, East Lansing, MI, 1964  
 (math) Graduate Asst. with sole responsibility for teaching "Elementary Mathematical Analysis"

B.A.: Michigan State University, East Lansing, MI, 1963  
 (math) Graduation with High Honors; Completed 4 year curriculum in 2 years

Federal Executive Institute, Charlottesville, VA  
 Senior Executive Training Program, 1984; Follow-on Programs 1985, 2011

Additional course work at Harvard University School of Public Health, Johns Hopkins University School of Hygiene and Public Health, and the Brookings Institution

### MEDICAL TRAINING AND CERTIFICATION

Internship: U.S. Public Health Service Hospital, San Francisco, 1967-68

Residency: U.S. Public Health Hospital, Baltimore, MD, 1968-70  
 (The name of this institution has been changed to Homewood Hospital Center.)

Certification: American Board of Family Medicine  
 Certified 1977; Recertified 1983, 1989, 1995, 2001, 2008, 2018  
 Subspecialty Certification in Geriatric Medicine 1996; Recertified 2006, 2016

### **CURRENT LICENSURE**

Medicine: Maryland, District of Columbia, California  
Law: Maryland, District of Columbia, U.S. Supreme Court

### **CURRENT PROFESSIONAL SOCIETIES**

Drug Information Association (Life Member)

President, 1984-85 and 1988-89

Board of Directors, 1982-1990; Annual Meeting Chair, 1991, 1994

American College of Legal Medicine (Fellow, 1973- )

Board of Governors, 1983-1993 and 2011- ; Treasurer, 1985-88 and 1990-91

Academy of Physicians in Clinical Research (Fellow, 2016- )

Treasurer, 2020-

Secretary, 2016-2017, 2019-2020

Immediate Past President, 2011-2012

President, 2010-2011

President-Elect, 2009; Secretary-Treasurer, 2008-2009

Board of Trustees, 1999-2003, 2008-2012; 2016- (<https://www.apcrnet.org/about/apcr-board-trustees>)

Vice President, AMA Relations, 1999-

President, Washington-Baltimore Chapter, 1999-2003

American (and Maryland) Academy of Family Physicians (Life Member) (Fellow, 1978- )

American Medical Association (Life Member)

Delegate Representing Academy of Physicians in Clinical Research, AMA House of Delegates, 2002-

MedChi – The MD State Medical Society; Baltimore City Medical Society (Life Member)

MedChi Delegate to U.S. Pharmacopeial Convention, 2008-

National Task Force on CME Provider/Industry Collaboration, 1992-2013

Membership Committee Chairman 2002-2005; Annual Meeting Chairman, 2003

American Public Health Association

Johns Hopkins Medical and Surgical Association

Academy of Medicine of Washington, DC

Board of Directors, 2013-2022

VP and President-Elect, 2016-2018

President, 2018-2020

Immediate Past President 2020-2022

Federal Bar Association (Chairman, Food and Drug Committee, 1976-79)

Delta Theta Phi Law Fraternity (Life Member)

American Bar Association; Maryland State Bar Association

Mathematical Association of America (50 Year Member)

Society for Industrial and Applied Mathematics (Life Member)

### **PROFESSIONAL AWARDS AND RECOGNITION**

Numerous from FDA

American Academy of Pharmaceutical Physicians President's Outstanding Service Award, 2003

American College of Legal Medicine President's Award, 1985, 86, 89, 91, 93; Gold Medal, 2003

Federal Bar Association Distinguished Service Award, 1977

Drug Information Association Outstanding Service Award, 1990

Phi Kappa Phi National Honorary Society (Life Member) ([http://en.wikipedia.org/wiki/Phi\\_Kappa\\_Phi](http://en.wikipedia.org/wiki/Phi_Kappa_Phi))

Listed Who's Who in America, Who's Who in the World, Who's Who in American Law, Who's Who in Finance and Industry, Who's Who in Medicine and Health Care, Who's Who in Science and Engineering, American Men and Women of Science, (<http://archive.is/Xb54O>)

Program Chair, 6<sup>th</sup> World Health Conference, "The Ongoing Transformation of Healthcare: Empowering Leadership for Change," April 15-16, 2004, The University of Chicago Pritzker School of Medicine  
Member and Chair of Membership Committee, Clinical Global Advisory Board, EduNeering, Inc., 2003-05  
Advisory Council, Commission for Certification of Healthcare CPD Professionals, 2006-12  
Chairman, American Board of Legal Medicine, 2011- ; Treasurer 2003-11  
([https://en.wikipedia.org/wiki/American\\_Board\\_of\\_Legal\\_Medicine](https://en.wikipedia.org/wiki/American_Board_of_Legal_Medicine)).  
Program Chair, FDLI/CBI Pharmaceutical Marketing Congress, 2005  
Program Co-Chair, Pharmaceutical Executive Medical Education Congress, 2006

### **EXPERIENCE IN PRIVATE MEDICAL PRACTICE AND ADMINISTRATION**

Physician: Part-time practice of family, emergency and geriatric medicine 1970-present

Director: Collington Continuing Care Retirement Community, Mitchellville, MD 2016-2022  
(<http://collington.kendal.org/board-of-directors>)

Medical Director: Maryland Manor Convalescent Center, Glen Burnie, MD 1975-1988

Medical Director: CHC Corporation, Baltimore, MD 1972-1976

Supervised physicians and attended patients, developed medical policy for health care facilities. Met with federal, state and local officials on regulatory matters and to express views on pending legislation and regulations. Problem solver throughout 2500 bed CHC chain

President: Zimmerly, Rheinstein & Josen, P.A., Severna Park, MD 1975-1976

Organized corporation to provide medical coverage for hospital emergency rooms. Recruited and supervised physicians. Marketed program to hospital administrators and medical staffs. Met with community leaders. (Sold interest in firm in 1976)

Physician and Instructor in Medicine: U of Maryland School of Medicine, Baltimore, MD 1970-1973

Attended patients and supervised medical students and house staff in medical and adult cardiac clinics at University of Maryland Hospital. Physician for students and staff.

### **BOOKS, MONOGRAPHS AND BOOK CHAPTERS**

Rheinstein, Peter H., M.D., J.D., M.S., Some Tips on FDA Etiquette I (Chapter in Pines, Wayne L. (Editor), "How to Work with the FDA, 2<sup>nd</sup> Ed," Food and Drug Law Institute, Washington, 2003)

Morris, Louis A., Rheinstein, Peter H., New Directions in Pharmaceutical Promotion: Regulatory Concerns and Contrivances (Chapter in Cato, AE, Sutton, S, Cato III, AE (Editors), "Clinical Drug Trials and Tribulations," Marcel Dekker, Inc., New York, 2002)

Montauk, Susan Louisa, M.D., Rheinstein, Peter H., M.D., J.D., M.S., Appropriate Use of Common OTC Analgesics and Cough and Cold Medications, An *American Family Physician* Monograph, American Academy of Family Physicians, Leawood, KS, 2002

Rheinstein, Peter H., M.D., J.D., M.S., Some Tips on FDA Etiquette I (Chapter in Pines, Wayne L. (Editor), "How to Work with the FDA," Food and Drug Law Institute, Washington, 2000)

Hoffman, Freddie Ann, M.D., Rheinstein, Peter H., M.D., J.D., M.S., Health Professionals and the Regulated Industry: The Laws and Regulations Enforced by the U.S. Food and Drug Administration (Chapter in American College of Legal Medicine, "Legal Medicine," Mosby, Inc., St. Louis, 4<sup>th</sup> ed. 1998, 5<sup>th</sup> ed. 2001, 6<sup>th</sup> ed. 2004, 7<sup>th</sup> ed., 2007) (Dr. Rheinstein also chaired the ACLM Publications Committee during production of both the first and second editions of this book.)

Rheinstein, Peter H., A Regulatory Response to Adverse Drug Events, (Chapter in Escovitz, Alan, PhD, Pathak, Dev S., DBA, Schneider, MS, RPh (Editors), Error Prevention and Reducing Adverse Drug Events, Pharmaceutical Products Press, New York, 1998.)

Cowan, Dale H., M.D., J.D., Kantorowitz, Jo Ann, J.D., Moskowitz, Jay, Ph.D., Rheinstein, Peter H., M.D., J.D., M.S. (Editors), "Human Organ Transplantation: Societal, Medical-Legal, Regulatory and Reimbursement Issues," American Society of Law and Medicine, 1987.

Morris, Louis A., Rheinstein, Peter H., The Package Insert as a License to Market, (Chapter in Cato, Allen E. (Editor), Clinical Drug Trials and Tribulations, Marcel Dekker, Inc., New York, 1988.)

Jones, J.K. (Dr. Rheinstein served as special editorial advisor), "The Good Housekeeping Guide to Medicines and Drugs," Hearst, New York, 1977.

#### **EDITORIAL BOARDS**

Pharmaceutical Development and Regulation (Adis), 2003-2006

Drug Information Journal (Drug Information Association), 1981-1992

#### **PUBLISHED ARTICLES**

More recent peer reviewed journal articles may be available at <https://orcid.org/0000-0002-4608-1665> and at <https://pubmed.ncbi.nlm.nih.gov/?term=rheinstein+p&sort=date>.

Steven Lehrer, Peter H Rheinstein. Marijuana and Myocardial Infarction in the UK Biobank Cohort. Cureus. 2022 Feb 9;14(2):e22054. doi: 10.7759/cureus.22054.  
(<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8826760>)

Steven Lehrer, Peter H Rheinstein. Constipation and Cigarette Smoking Are Independent Influences for Parkinson's Disease. Cureus. 2022 Jan 28;14(1):e21689. doi: 10.7759/cureus.21689. eCollection 2022 Jan. PMID: 35145822 DOI: 10.7759/cureus.21689  
(<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8803378>)

S Lehrer, P H Rheinstein. Marijuana smoking and cataract. J Fr Ophtalmol. 2022 Mar;45(3):267-271. doi: 10.1016/j.jfo.2021.12.008. PMID: 35093261 DOI: 10.1016/j.jfo.2021.12.008  
(<https://www.sciencedirect.com/science/article/abs/pii/S0181551222000146?via%3Dihub>)

S Lehrer, P H Rheinstein. Cannabis smoking and glaucoma in the UK Biobank cohort. J Fr Ophtalmol. 2022 Jan 26;S0181-5512(22)00024-9. doi: 10.1016/j.jfo.2021.12.012. Online ahead of print.  
(<https://www.sciencedirect.com/science/article/abs/pii/S0181551222000249?via%3Dihub>)

Steven Lehrer, Peter H Rheinstejn, James Schmeidler. A Component or Multiple Components of Bleeding Gums May Ameliorate Both Glaucoma and Alzheimer's Disease. PMID: 35028240 PMCID: PMC8747976 DOI: 10.7759/cureus.21004.

(<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8747976>)

Lehrer S, Rheinstejn PH. Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort. *Am J Clin Oncol*. 2021 Jul 1;44(7):299-300. doi: 10.1097/COC.0000000000000833. PMID: 34008499

([https://journals.lww.com/amjclinicaloncology/Abstract/2021/07000/Endometrial\\_Cancer,\\_BRCA\\_1,\\_and\\_BRCA2\\_in\\_the\\_UK.1.aspx](https://journals.lww.com/amjclinicaloncology/Abstract/2021/07000/Endometrial_Cancer,_BRCA_1,_and_BRCA2_in_the_UK.1.aspx))

Steven Lehrer, Peter H Rheinstejn. Alzheimer's Disease and Parkinson's Disease May Result from Reactivation of Embryologic Pathways Silenced at Birth. *Discov Med*. Mar-Apr 2021;31(163):89-94. PMID: 34965376 PMCID.

(<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8717685>)

Steven Lehrer, Peter H Rheinstejn. Druggable genetic targets in endometrial cancer. *Cancer Treat Res Commun*. 2021 Dec 17;30:100502. doi: 10.1016/j.ctarc.2021.100502. Online ahead of print. PMID: 34933203 DOI: 10.1016/j.ctarc.2021.100502

(<https://www.sciencedirect.com/science/article/pii/S2468294221001982?via%3Dihub>)

Steven Lehrer, Peter H Rheinstejn. Herpes Zoster Vaccination Reduces Risk of Dementia. *In Vivo*. Nov-Dec 2021;35(6):3271-3275. doi: 10.21873/invivo.12622, PMID: 34697158 PMCID: PMC8627719 DOI: 10.21873/invivo.12622 (<https://iv.iijournals.org/content/35/6/3271.long>)

Steven Lehrer, Peter H Rheinstejn. Common drugs, vitamins, nutritional supplements and COVID-19 mortality. *Int J Funct Nutr*. Jan-Feb 2021;2(1):4. doi: 10.3892/ijfn.2021.14. Epub 2021 Mar 18. PMID: 34337612 PMCID: DOI: 10.3892/ijfn.2021.14.

(<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8323622>)

Steven Lehrer, Peter H Rheinstejn. FBXW7, L1CAM, and TGM2 in endometrial cancer. *Cancer*. 2021 Nov 1;127(21):4103-4104. doi: 10.1002/cncr.33782. Epub 2021 Jul 29. MID: 34324708 DOI: 10.1002/cncr.33782. (<https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33782>)

Steven Lehrer, Peter H Rheinstejn. Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort. *Am J Clin Oncol*. 2021 Jul 1;44(7):299-300. doi: 10.1097/COC.0000000000000833.

([https://journals.lww.com/amjclinicaloncology/Abstract/2021/07000/Endometrial\\_Cancer,\\_BRCA\\_1,\\_and\\_BRCA2\\_in\\_the\\_UK.1.aspx](https://journals.lww.com/amjclinicaloncology/Abstract/2021/07000/Endometrial_Cancer,_BRCA_1,_and_BRCA2_in_the_UK.1.aspx))

Lehrer S, Rheinstejn P. Eyeglasses Reduce Risk of COVID-19 Infection. *In Vivo*. 2021 May-Jun;35(3):1581-1582. doi: 10.21873/invivo.12414

(<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193301>)

Lehrer S, Rheinstejn PH. ABO blood groups, COVID-19 infection and mortality, *Blood Cells Mol Dis*. 2021 Jul;89:102571. doi: 10.1016/j.bcmd.2021.102571. Epub 2021 Apr 21.

(<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059281>)



Lehrer S, Rheinstei PH. Breast Cancer, Alzheimer's Disease, and APOE4 Allele in the UK Biobank Cohort. *J Alzheimers Dis Rep*. 2021 Jan 20;5(1):49-53. doi: 10.3233/ADR-200266. (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902990>)

Lehrer S, Rheinstei PH. BIN1 rs744373 SNP and COVID-19 mortality. *World Acad Sci J*. 2021 Mar-Apr;3(2):13. doi: 10.3892/wasj.2021.84. Epub 2021 Jan 14. (<https://www.spandidos-publications.com/10.3892/wasj.2021.84>)

Lehrer S, Rheinstei PH. Homozygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort. *In Vivo*. 2021 Mar-Apr;35(2):965-968. doi: 10.21873/invivo.12338. (<https://iv.iarjournals.org/content/35/2/965.long>)

Lehrer S, Rheinstei PH. The ADRB1 (Adrenoceptor Beta 1) and ADRB2 genes significantly co-express with commonly mutated genes in prostate cancer. *Discov Med*. Nov-Dec 2020;30(161):163-171. (<https://www.discoverymedicine.com/Steven-Lehrer/2020/12/adrb1-adrenoceptor-beta-1-adrb2-co-express-in-prostate-cancer>)

Lehrer S, Rheinstei PH. The actinomycin D molecule docks to a hydrophilic section of the SOX2 high-mobility group (HMG) domain. *Neuro Oncol*. 2021 Mar 25;23(3):500-501. doi: 10.1093/neuonc/noaa299. (<https://academic.oup.com/neuro-oncology/article-lookup/doi/10.1093/neuonc/noaa299>)

Lehrer S, Rheinstei PH. Statins combined with niacin reduce the risk of peripheral neuropathy. *Int J Funct Nutr*. 2020 Sep-Oct;1(1):3. doi: 10.3892/ijfn.2020.3. Epub 2020 Jun 9. (<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7737454>)

Lehrer S, Rheinstei PH. Alignment of Alzheimer's Disease Amyloid- $\beta$  Peptide and Herpes Simplex Virus-1 pUL15 C-Terminal Nuclease Domain *J Alzheimers Dis Rep*. 2020 Sep 9;4(1):373-377. doi: 10.3233/ADR-200231 (<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7592838>)

Lehrer S, Rheinstei PH. Alignment of Alzheimer's disease amyloid  $\beta$ -peptide and klotho *World Acad Sci J*. 2020 Nov-Dec;2(6):27. doi: 10.3892/wasj.2020.68. Epub 2020 Sep 22. (<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7521834>)

Lehrer S, Rheinstei PH. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. *In Vivo*. 2020 Sep-Oct;34(5):3023-3026. doi: 10.21873/invivo.12134. (<https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7652439>)

Rheinstei Peter. Opinion: Research protections will beat crises like COVID-19. *The Columbus Dispatch* 11 August 2020. (<https://www.dispatch.com/opinion/20200811/column-research-protections-will-beat-crises-like-covid-19>)

Lehrer S, Rheinstei PH. Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening. *J Natl Cancer Inst*. 2020 Jun 30;djaa092. doi: 10.1093/jnci/djaa092. [Online ahead of print] (<https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaa092/5865274>)



Lehrer S, Rheinstei PH. Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer. *Am J Clin Oncol*. 2020 Jun 19. doi: 10.1097/COC.0000000000000727. PMID: 32568785 [Online ahead of print]  
 (([https://journals.lww.com/amjclinicaloncology/Abstract/9000/Alzheimer\\_Gene\\_BIN1\\_may\\_Simultaneously\\_Influence.98656.aspx](https://journals.lww.com/amjclinicaloncology/Abstract/9000/Alzheimer_Gene_BIN1_may_Simultaneously_Influence.98656.aspx))

Lehrer S, Rheinstei PH. Human Gene Sequences in SARS-CoV-2 and Other Viruses. *In Vivo*. 2020;34(3 Suppl):1633-1636. doi:10.21873/invivo.11954  
 ([http://iv.iijournals.org/content/34/3\\_suppl/1633.long](http://iv.iijournals.org/content/34/3_suppl/1633.long))

Lehrer S, Rheinstei PH. SARS-CoV-2 orf1b Gene Sequence in the NTNG1 Gene on Human Chromosome 1. *In Vivo*. 2020;34(3 Suppl):1629-1632. doi:10.21873/invivo.11953  
 ([http://iv.iijournals.org/content/34/3\\_suppl/1629.long](http://iv.iijournals.org/content/34/3_suppl/1629.long))

Lehrer S, Rheinstei PH. Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer Cancer Genomics Proteomics. May-Jun 2020;17(3):271-275. doi: 10.21873/cgp.20187  
 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259887>)

Lehrer S, Rheinstei PH. The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age. *Cancer*. 2020 Feb 19. doi: 10.1002/cncr.32788. [Epub ahead of print] No abstract available. PMID: 32073649  
 (<https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32788>)

Lehrer S, Rheinstei PH. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce suicidal ideation and depression. *Discov Med*. 2019 Oct;28(154):205-212. PMID: 31928628  
 (<http://www.discoverymedicine.com/Steven-Lehrer/2019/10/nonsteroidal-anti-inflammatory-drugs-nsaids-reduce-suicidal-ideation-and-depression>)

Rheinstei Peter. Opinion: House drug bill dooms medical research. *Detroit News* 20 November 2019.  
 (<https://www.detroitnews.com/story/opinion/2019/11/21/opinion-house-drug-bill-dooms-medical-research/4232138002>)

Lehrer S, Rheinstei PH. The virology of breast cancer: viruses as the potential causative agents of breast tumorigenesis. *Discov Med*. 2019 Mar;27(148):163-166. PMID: 31095925  
 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543532>)

Lehrer S, Green S, Dembitzer FR, Rheinstei PH, Rosenzweig KE. von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53. *Brain Tumor Res Treat*. 2019 Apr;7(1):33-38. doi: 10.14791/btrt.2019.7.e20. PMID: 31062529 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504758>)

Lehrer S, Green S, Dembitzer FR, Rheinstei PH, Rosenzweig KE. Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype. *Cancer Genomics Proteomics*. 2019 May-Jun;16(3):147-153. doi: 10.21873/cgp.20120.  
 (<http://cgp.iijournals.org/content/16/3/147.long>)

Lehrer S, Rheinstei PH. Mouse mammary tumor viral env sequences are not present in the human genome but are present in breast tumors and normal breast tissues. *Virus Res*. 2019 Apr 3;266:43-47. doi: 10.1016/j.virusres.2019.03.011. [Epub ahead of print]  
 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510484>)

Lehrer S, Rhoinstein PH. Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer's disease: a new route of administration. *Discov Med*. 2019 Jan;27(146):37-43.

(<http://www.discoverymedicine.com/Steven-Lehrer/2019/01/transspinal-delivery-of-drugs-by-back-of-neck-transdermal-patch-for-alzheimers-disease>)

Lehrer S, Rhoinstein PH, Rosenzweig KE. Allergy may confer better survival on patients with gliomas. *Clin Neurol Neurosurg*. 2019 Feb;177:63-67. doi: 10.1016/j.clineuro.2018.12.021. Epub 2018 Dec 31.

(<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351160>)

Lehrer S, Rhoinstein PH. Three Poliovirus Sequences in the Human Genome Associated With Colorectal Cancer. *Cancer Genomics Proteomics*. 2019 Jan-Feb;16(1):65-70. doi: 10.21873/cgp.20112.

(<http://cgp.iarjournals.org/content/16/1/65.long>)

Rhoinstein Peter. Gutting Drug Patents Puts Lives at Risk. *National Review* 2 October 2018.

(<https://www.nationalreview.com/2018/10/gutting-drug-patents-puts-lives-at-risk>)

Lehrer S, Rhoinstein PH. Inverse Relationship Between Polio Incidence in the US and Colorectal Cancer. *In Vivo*. 2018 Nov-Dec;32(6):1485-1489. doi: 10.21873/invivo.11404

(<http://iv.iarjournals.org/content/32/6/1485.long>)

Lehrer S, Rhoinstein PH. Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer. *Cancer Genomics Proteomics*. 2018 Sep-Oct;15(5):387-393. doi: 10.21873/cgp.20097.

(<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199572>)

Lehrer S, Rhoinstein PH, Rosenzweig KE. Increased expression of von Willebrand factor gene is associated with poorer survival in primary lower grade glioma. *Glioma*. 2018 Jul-Aug;1(4):132-135. doi: 10.4103/glioma.glioma\_17\_18. Epub 2018 Aug 30.

(<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157623>)

Lehrer S, Rhoinstein PH, Rosenzweig KE. Loss of MycBP may be associated with the improving survival in 1P co-deletion of lower grade glioma patients. *Clinical Neurology and Neurosurgery*, vol 172, September 2018, Pages 112-115.

(<https://doi.org/10.1016/j.clineuro.2018.07.003>)

Lehrer S, Rhoinstein PH, Rosenzweig KE. No Relationship of Anti-Androgens to Alzheimer's Disease or Cognitive Disorder in the MedWatch Database. *J Alzheimers Dis Rep*. 2018 Jun 30;2(1):123-127. doi: 10.3233/ADR-180052.

(<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159660>)

Lehrer S, Rhoinstein PH, Rosenzweig KE. Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. *Cancer*. 2018 Mar 15. doi: 10.1002/cncr.31262. 2253-2253. PMID: 29543320

(<https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31262>)

Lehrer S, Dembitzer FR, Rhoinstein PH, Rosenzweig KE. In primary glioblastoma fewer tumor copy number segments of the F13A1 gene are associated with poorer survival. *Thrombosis Research* DOI:

(<https://doi.org/10.1016/j.thromres.2018.05.001>)

Lehrer S, Rhoinstein PH, Rosenzweig K. Mutations of the PDE5A gene confer a survival advantage in patients with colon cancer; *Cancer Prevention Research*

(<http://cancerpreventionresearch.aacrjournals.org/content/early/2018/05/03/1940-6207.CAPR-18-0105.long>)

Steven Lehrer, Peter H. Rheinstein and Kenneth E. Rosenzweig. Periodontal Disease and Incident Cancer—Letter, May 2018 (<http://cebp.aacrjournals.org/content/27/5/614.long>)

Lehrer S, Rheinstein PH. Nasal steroids as a possible treatment for Alzheimer's disease. *Discov Med*. 2017 Oct;24(132):147-152. PMID: 29272691 (<http://www.discoverymedicine.com/Steven-Lehrer/2017/10/nasal-steroids-as-a-possible-treatment-for-alzheimers-disease>)

Lehrer S. Rheinstein P.H., Rosenzweig K.E. Association of Radon Background and Total Background Ionizing Radiation with Alzheimer's Disease Deaths in U.S. States. *J Alzheimers Dis*. 2017 Jun 22. doi: 10.3233/JAD-170308. [Epub ahead of print] (<http://content.iospress.com/articles/journal-of-alzheimers-disease/jad170308>)

Lehrer S, Rheinstein PH, Green S, Rosenzweig K.E. Young premenopausal women with breast cancer, especially estrogen receptor negative, are at significantly increased risk for subsequent ovarian cancer. *Discov Med*. 2016 Oct;22(121):209-213. PMID: 27875672 (<http://www.discoverymedicine.com/Steven-Lehrer/2016/10/young-premenopausal-women-with-breast-cancer-especially-estrogen-receptor-negative-are-at-significantly-increased-risk-for-subsequent-ovarian-cancer>)

Lehrer S. and Rheinstein P. Relation of Poor Memory to Soluble Tumor Necrosis Factor Receptor Type Two (sTNF-RII). *Am J Alzheimers Dis Other Demen*. 2016 Aug;31(5):457-8. doi: (<http://journals.sagepub.com/doi/10.1177/1533317515622284>). Epub 2015 Dec 24

Rheinstein P. The Wrong Way to Control Drug Prices. *The Washington Times* 19 April 2016. (<http://www.washingtontimes.com/news/2016/apr/19/peter-rheinstein-the-wrong-way-to-control-drug-pri/?page=all#pagebreak>)

Lehrer S. and Rheinstein P. Two compartment model of MSH/ACTH may be a surrogate for intranasal insulin central nervous system kinetics. *Journal of Alzheimer's Disease* 31 July 2015.

Lehrer S. and Rheinstein P. Is Alzheimer's Disease Autoimmune Inflammation of the Brain That Can be Treated With Nasal Nonsteroidal Anti-Inflammatory Drugs? *Am J Alzheimers Dis Other Demen*. 2015 May;30(3):225-7.

Lehrer S, Rheinstein P, Mulshine J. Inhaled buformin for lymphangioleiomyomatosis and early (airway confined) lung cancer. *American Association for Cancer Research Annual Meeting Abstracts 2014*;14-A-638-AACR.

Koren, MJ, Koski G, Reed DP, Rheinstein PH, Silva H, Stonier P, Seltzer J. APCR Physician Investigator Competence Statement. *The Monitor* 2011 Aug;25(4):79-82. ([https://www.apcrnet.org/sites/default/files/apcr\\_consensus\\_statement.pdf](https://www.apcrnet.org/sites/default/files/apcr_consensus_statement.pdf))

Rheinstein PH. A Year of "Profound Importance." *The Monitor* 2010 Feb;24(1):73-74.

Rheinstein PH. The Clinical Investigator's Responsibility as a Teacher. *The Monitor* 2009 Sep;24(5):75-6.

Rheinstein PH. Opening borders to foreign drugs is wrong prescription. *Baltimore Business J*. 2003; July8; Reprinted as Opening up U.S. borders for prescription drugs unhealthy. *Baltimore Business J*. 2003; Sep8; (See <http://www.bizjournals.com/baltimore/stories/2003/09/08/editorial2.html?t=printable>.)

Rheinstein PH. Overview of the US Food and Drug Administration's reform legislation. *Clin Ther*. 1998;20 Suppl C:C4-11.

- Rheinstein PH, Tsai VW. Keeping abreast of new drug approvals and labeling changes. *Am Fam Physician*. 1998 Sep 15;58(4):995-8.
- Rheinstein PH, Akbari B. Significant FDA approvals in 1997. *Am Fam Physician*. 1998 Jun;57(11):2865-8.
- Rheinstein PH. Prescription to over-the-counter drug switches. *Am Fam Physician*. 1998 Sep 15;56(4):1211-4.
- Rheinstein PH. Significant FDA approvals in 1996. *Am Fam Physician*. 1997 Jun;55(8):2855-8.
- Rheinstein PH, McGinnis TJ, Nightingale SL. Children and tobacco: the FDA's final rule. *Am Fam Physician*. 1997 Mar;55(4):1441-4.
- Rheinstein PH. Seven tips for sun sense. *Am Fam Physician*. 1996 Sep 15;54(4):1385-8.
- Rheinstein PH, McGinnis TJ. Ways to Access FDA Information. *Am Fam Physician*. 1996 Jul;54(1):353-8.
- Rheinstein PH. Significant FDA approvals in 1995. *Am Fam Physician*. 1996 Apr;53(5):1871-4.
- Rheinstein PH, McGinnis TJ, Nightingale SL. The patient information and education initiative. *Am Fam Physician*. 1995 Dec;52(8):2377-8, 2381-2.
- Rheinstein PH, McGinnis TJ. Children and tobacco: the Clinton administration proposal. *Am Fam Physician*. 1995 Sep 15;52(4):1205-8.
- Rheinstein PH, Thomas A. Home test kits and monitors. *Am Fam Physician*. 1995 Jul;52(1):293-6.
- Rheinstein PH. Significant FDA approvals in 1994. *Am Fam Physician*. 1995 Mar;51(4):888-90.
- Rheinstein PH. Avoiding problems with liquid medications and dosing devices. *Am Fam Physician*. 1994 Dec;50(8):1771-2.
- Nightingale SL, Kimbrough CA, Rheinstein PH. Access to investigational drugs for treatment purposes. *Am Fam Physician*. 1994 Sep 15;50(4):845-7.
- Hoffman FA, Rheinstein PH, Houn F. The Mammography Quality Standards Act of 1992. *Am Fam Physician*. 1994 Jun;49(8):1965-70.
- Rheinstein PH. The generic drug approval process. *Am Fam Physician*. 1993 Dec;48(8):1357-60.
- Rheinstein PH. MedWatch: the FDA medical products reporting program. *Am Fam Physician*. 1993 Sep 15;48(4):636-8.
- Rheinstein PH, Klontz KC. Shellfish-borne illnesses. *Am Fam Physician*. 1993 Mar;47(4):1837-40.
- Rheinstein PH. Update of food labeling. *Am Fam Physician*. 1993 Mar;47(4):979-82.
- Rheinstein PH. Healthy people 2000 initiative. *Am Fam Physician*. 1992 Dec;46(6):1829-32.
- Rheinstein PH. Reporting of adverse drug events: a key to postmarketing drug safety. *Am Fam Physician*. 1992 Sep;46(3):873-4.

Lazar EJ, Banks D, Graham C, Adams D, Rheinstein PH, Gross M, Witt AM. Drug company sponsorship of education: the response to the FDA draft concept paper (letter). *JAMA*. 1992 Jul 1;268(1):53-4.

Rheinstein PH, McGinnis TJ. Medication Errors. *Am Fam Physician*. 1992 Jun;45(6):2720-2.

Rheinstein PH, Bagley GP. Food labeling reforms for 1992. *Am Fam Physician*. 1992 Mar;45(3):1349-53.

Rheinstein PH, Hoffman FA. Update on Breast Implants. *Am Fam Physician*. 1991 Dec;44(6):2227-9.

Rheinstein PH. The FDA as an information source for family physicians. *Am Fam Physician*. 1991 Sep;44(3):1037-41.

Rheinstein PH. Significant FDA approvals in 1990. *Am Fam Physician*. 1991 Jun;43(6):2257-8.

Peck CC, Rheinstein PH. FDA regulation of prescription drug advertising. *JAMA*. 1990 Nov 14;264(18):2424-5.

Rheinstein PH. Regulatory Status of pancreatic enzyme preparations. *JAMA*. 1990 May 9;263(18):2491-2.

Rheinstein PH. Therapeutic Inequivalence. *Drug Saf*. 1990;5 suppl 1:114-9.

Faich GA, Morrison J, Dutra EV Jr, Hare DB, Rheinstein PH. Reassurance about generic drugs? *N Engl J Med*. 1987 Jun 4;316(23):1473-5.

Rheinstein PH, Mazis MB. Regulation of O-T-C drug advertising: the FDA "prescription". *J Am Pharm Assoc*. 1976 Sep;16(9):505-6, 524.

Rheinstein PH. Drug Labeling as a standard for medical care. *J Leg Med (NY)*. 1976 Jan;4(1):22-4.

**Presentations and references are available on request.**

### **SOCIAL MEMBERSHIPS**

Intercultural Friends Foundation (Foreign Student Exchange Program) (Vice-President, 1998- )  
(<http://www.iffusa.org>)

Michigan State University (MSU) Alumni Assn. (Life Member) (President's Club)

MSU Honors College Alumni Assn. (Member, Executive Committee, 1998-2001, President, 2000-2001)

Federal Executive Institute Alumni Assn. (Life Member)

Johns Hopkins University Alumni Assn. (Life Member)

National Association of Retired Federal Employees (Life Member)

University of Maryland Alumni Assn. (Life Member),

Annapolis Yacht Club

Chartwell Golf and Country Club

The Johns Hopkins Club

Mensa (Life Member)

U.S. Power Squadrons

### **PERSONAL**

**Born:** Cleveland, Ohio, September 7, 1943

Married: Miriam Ruth Weissman; February 22, 1969; President, Intercultural Friends Foundation,  
Severna Park, MD

Hobbies: Physical Fitness, Boating